Deteron

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Deteron

Deteron is a prescription-only, psychotropic agent containing the active ingredient Risperidone. It is fundamentally classified as a Second-Generation Antipsychotic (SGA), also known as an Atypical Antipsychotic.


Quick Facts

Property Description
Active ingredient Risperidone
Forms Oral tablets, Oral solution, Long-acting injection
Pharmacological class Atypical Antipsychotic (Second-Generation Antipsychotic)
Chemical group Benzisoxazole derivatives
Origin Synthetic

What Type of Medicine is Deteron (Risperidone)?

Deteron belongs to the Atypical Antipsychotic pharmacological class, which consists of synthetic compounds used to modulate and stabilize brain chemistry. The core substance, Risperidone, is structurally part of the benzisoxazole derivatives chemical group. Risperidone is clinically recognized for its broad-spectrum efficacy in addressing severe mental health disorders and is characterized by its unique receptor binding profile. As a single-entity product, its action is defined by the properties of Risperidone and its active metabolite, 9-hydroxyrisperidone, which also possesses significant pharmacological activity. Popular brands containing this same formulation include Risperdal and Risvan.

Composition and Available Forms of Deteron

The primary composition of Deteron centers on its active ingredient, Risperidone. The medication is offered in several distinct pharmaceutical preparations to accommodate different clinical needs. These preparations include common oral tablets and an oral solution for daily consumption, as well as forms intended for parenteral routes of administration, specifically the long-acting intramuscular injection and the extended-release suspension for subcutaneous use. The availability of the long-acting injection is a key differentiator for the Risperidone formulation, offering therapeutic consistency. These varied forms ensure flexibility in delivering Risperidone consistently to the patient.

Deteron’s General Therapeutic Purpose

Deteron’s general purpose is to modulate and stabilize the signaling activity of key natural substances in the brain, functioning as a selective monoaminergic antagonist. This involves regulating the influence of dopamine (D2) and serotonin (5HT2) receptors, which are integral to processes of mood and thought. This mechanism helps restore the balance of these substances in the brain, helping to stabilize mood and thinking processes. Risperidone is typically used in scenarios requiring the long-term stabilization of severe emotional and mental regulation issues. By acting across these primary signaling systems, the drug aims to achieve neurochemical balance, helping to stabilize overall mental function and reduce disruptions like disorganized thinking and severe mood disturbances.

Regulatory References

  1. National Institutes of Health/NIH
  2. MedlinePlus/NIH

What side effects are possible with Deteron?

Possible Side Effects and Safety Information

The safety profile for Deteron (Risperidone) is organized by regulatory agencies based on the incidence and nature of reported adverse reactions. This classification helps define the risk profile and what patients may experience.


Frequency-Classified Adverse Reactions

The most commonly documented effects are classified by their observed frequency in clinical trials. Very common adverse reactions (occurring in 1 out of 10 people or more) typically include insomnia, sedation or somnolence, Parkinsonism (a type of Extrapyramidal Symptom), and headache. Common adverse reactions often include dizziness, tremor, increased weight, and nausea.


Systemic Safety Concerns and Serious Reactions

The adverse reactions are grouped by the affected physiological system. Effects are often noted in the Nervous System (e.g., EPS) and Metabolism and Nutrition (e.g., weight gain, dyslipidemia, and the potential for new-onset Diabetes Mellitus). Endocrine disorders, such as elevated prolactin levels (hyperprolactinemia), are also documented.

Regulatory documents highlight rare, but clinically significant, serious adverse reactions, including Neuroleptic Malignant Syndrome (NMS) and Tardive Dyskinesia (TD), an involuntary movement disorder associated with long-term use. A decrease in white blood cell counts, such as agranulocytosis, is also noted.


Population-Specific and Time-Related Notes

The official labeling includes specific safety considerations for certain patient groups. Older adults with dementia-related psychosis have a documented increased risk of mortality and Cerebrovascular Adverse Events (CVAE) compared to placebo. Additionally, pediatric patients often show a higher incidence of weight gain.

Some effects, such as orthostatic hypotension and sedation, are noted to be more likely at the start of treatment or during dose increases, while risks like Tardive Dyskinesia are associated with long-term exposure.

Overdose and Emergency Response

Deteron Overdose and when to seek help

Overdose scope Details (Official Regulatory Information Only)
Documented overdose presentations Overdose is officially documented to present as an exaggeration of the drug's known effects, including drowsiness, sedation, and somnolence. Motor disturbances such as Extrapyramidal Symptoms (EPS) and seizures are also reported clinical manifestations.
Physiological systems affected The primary systems affected are the Central Nervous System (CNS) and the Cardiovascular system. Serious cardiac effects documented include tachycardia (rapid heartbeat), hypotension (low blood pressure), QT prolongation (an irregular heart rhythm), and potential ventricular arrhythmia.
Population-specific overdose notes Official labeling notes that children may exhibit increased susceptibility to Extrapyramidal Symptoms (EPS) in overdose situations.
Emergency-response statements No specific antidote is known to reverse the effects. Management is strictly defined as symptomatic and supportive. Supportive measures include ensuring an adequate airway and administering anticholinergic agents for severe EPS, if required.
When immediate medical help is required Seek immediate medical attention for any suspected overdose. Emergency services must be contacted immediately if the patient has collapsed, had a seizure, has trouble breathing, or cannot be awakened.

Resulting Overdose Structure

Official regulatory statements regarding overdose include:

  • Overdose is documented by symptoms of CNS depression and motor disturbances, with the potential for life-threatening cardiovascular complications and seizures.
  • Due to the risk of serious cardiac effects, continuous monitoring of vital signs and the ECG is required until the patient fully recovers from the overdose event.
  • Management is wholly supportive, as there is no specific antidote officially documented.

Connection to the overall overdose profile: Regulatory documents define the overdose profile by emphasizing the potential for both severe central nervous system depression and critical cardiovascular instability. This dual risk dictates the official emergency actions, mandating that immediate medical help be sought for a suspected overdose and requiring intensive, supportive treatment with continuous cardiac monitoring.

Therapeutic Uses of Deteron

What Deteron Treats: Main Uses and Benefits

Deteron (Risperidone) may be part of symptomatic management for severe or disruptive symptom patterns across key psychiatric domains. It is applied in clinical settings that involve acute or unstable symptom patterns where supportive symptom management is appropriate. The therapeutic areas of use include symptomatic support for Schizophrenia in adults and adolescents, acute manic or mixed episodes of Bipolar I Disorder, and irritability associated with Autistic Disorder in children and adolescents.

This medication helps address symptom clusters that may become intense or disruptive, such as hallucinations, delusions, racing thoughts, and severe aggression.

“It assists with maintaining functional stability during phases when symptoms become more noticeable.”

The use is relevant in situations where symptoms interfere with routine activities. Deteron provides support that helps ease the overall symptom burden, provides supportive relief that helps patients cope more steadily with difficult episodes.


Quick Fact: Relief for Disruptions in Thought and Mood Deteron contributes to improved comfort during symptomatic periods by addressing psychotic manifestations and helping to ease the symptom burden associated with acute mood episodes.

Eligibility and Restrictions for Use

Eligibility Profile and Restrictions for Deteron

Official regulatory documents define specific populations who must not use Deteron (contraindicated) and those for whom use is restricted or not recommended.


Contraindicated Populations (Must Not Use)

Contraindication Basis for Exclusion (Official Classification)
Urinary Retention Physiological obstruction/risk
Gastric Retention Physiological obstruction/risk
Uncontrolled Narrow-Angle Glaucoma Specific pre-existing condition
Known Hypersensitivity Documented allergy to the drug substance or its ingredients

Restricted and Non-Eligible Groups

  • Severe Hepatic Impairment (Child-Pugh Class C): Use is not recommended.
  • Severe Renal Impairment (Creatinine Clearance CCr < 10 mL/min): Use is not recommended; patients with CCr: 10–30 mL/min require caution and dose adjustment.
  • Pediatric Use: Efficacy and safety have not been established.
  • Lactation: Use is not recommended (should not be administered to nursing mothers).

Use is allowed for adult patients who do not have any of the documented contraindications and are not in a specific high-risk category (e.g., severe organ impairment) that mandates exclusion or mandatory dose adjustment.

What should I know about interactions with other medicines?

Deteron Interactions with other medicines and products

Official regulatory information documents interactions involving two primary mechanisms: the alteration of drug exposure and additive pharmacodynamic effects. Risperidone, the active substance in Deteron, is metabolized primarily by the CYP2D6 enzyme and is a substrate for the P-glycoprotein (P-gp) transporter, factors which structure its pharmacokinetic interaction profile.

Pharmacokinetic Interaction Patterns

Substances that inhibit CYP2D6, such as Fluoxetine and Paroxetine, may significantly increase the plasma concentration of the active antipsychotic fraction. Conversely, enzyme inducers like Carbamazepine and Phenytoin may decrease the exposure of the active fraction. P-gp inhibitors like Verapamil are also documented to increase Risperidone concentration.

Pharmacodynamic and Substance Interactions

Co-administration with other Centrally Acting Agents, including alcohol, may result in an additive CNS depressant effect. A risk of additive QT interval prolongation exists when Deteron is combined with other agents that prolong the QT interval. Furthermore, combining Deteron with antihypertensive agents may lead to additive hypotensive effects. The combination of Risperidone and Furosemide has been associated with a higher incidence of mortality in elderly patients with dementia. The pharmacokinetics of oral Risperidone are not clinically affected by food.

Mechanism of Action

Deteron (Risperidone) functions as a monoamine modulator, acting through a dual receptor antagonism that modulates neurochemical signaling within the brain. Its mechanism is defined by the combined effect across central and peripheral systems.


Dual Receptor Antagonism and Neurochemical Modulation

The drug's primary mechanism involves the high-affinity blockade (antagonism) of both the Dopamine Type 2 ( D2) receptor and the Serotonin Type 2 ( 5-HT2 A) receptor in the Central Nervous System (CNS). This combined antagonism exerts a two-part effect: the D2 blockade reduces dopamine signaling in relevant pathways, while the 5-HT2 A blockade simultaneously facilitates dopamine release in the prefrontal cortex, modulating processes driven by these distinct signaling patterns. This interaction influences underlying neurochemical signaling.


Systemic and Endocrine Pathway Modulation

In addition to its central actions, Deteron engages mechanisms that influence other regulatory systems. It blocks the Alpha-1 (alpha1) adrenergic receptor, leading to modulation of peripheral vascular tone, and it also blocks the Histamine H1 receptor, which modulates central arousal. Furthermore, the D2 receptor antagonism in the tuberoinfundibular pathway disinhibits the release of prolactin, initiating a specific endocrine consequence.

Dosage and Administration Information

Deteron (Risperidone) is officially administered via the oral route using tablets, solution, or orally disintegrating tablets (ODT), or via the parenteral route using long-acting deep intramuscular (IM) or subcutaneous (SC) injections. The choice of administration route dictates the required frequency and professional supervision setting.

For oral administration, dosing generally begins at a low starting amount, such as 2 mg/day for schizophrenia in adults. Dosage initiation for older adults or those with renal or hepatic impairment is lower, typically starting at 0.5 mg twice daily. Dose adjustments (titration) are made gradually, usually at intervals of no less than 24 hours. Oral tablets and the solution can be taken with or without food. However, the oral solution must be mixed only with approved beverages, such as water or coffee, and is strictly prohibited from being mixed with cola or tea.

When utilizing the long-acting injection forms, the regimen shifts to an intermittent schedule (e.g., bi-weekly or monthly), administered by a healthcare professional. For specific bi-weekly IM injections, continuous oral antipsychotic coverage is mandatory for the first three weeks following the first injection to cover the absorption lag time. The injection preparations must not be administered intravenously (IV) under any circumstance. If a scheduled injection is missed, it should be administered as soon as possible, without subsequently altering the frequency beyond the defined interval.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Deteron (Risperidone)

This overview describes the types of clinical studies that have been conducted to evaluate Deteron and what the research evidence has explored, without giving medical advice or guidance on how the medicine should be used.


Evidence Supporting Use in Schizophrenia

Research for Deteron in Schizophrenia has been evaluated in numerous short-term Randomized Controlled Trials (RCTs) and longer-term maintenance studies. These studies have included both adults and adolescents aged 13 and older who were experiencing conditions of the type studied. Researchers designed these studies to measure symptom intensity using standardized assessments and tracked factors like the rate of relapse or rehospitalization, particularly for the long-acting injectable (LAI) formulation. Studies monitored patterns observed in the data related to symptom severity scores. Long-term research describes patterns related to maintenance and recurrence prevention.

Despite the large volume of research, long-term effects are not fully established regarding comprehensive functional and cognitive outcomes. Also, follow-up durations were limited in many of the initial trials.


Evidence Supporting Use in Acute Bipolar I Episodes

Research exploring the use of Deteron for acute manic or mixed episodes mainly involves short-term RCTs. These studies were conducted during periods of increased symptom activity, and Deteron was evaluated in subjects as a single treatment or when added to other standard mood stabilizers. The primary focus of this research was on outcomes capturing phases of heightened symptom activity, measured using tools such as the Young Mania Rating Scale (YMRS). Research explores changes measured during the study period on manic symptom scales. Findings describe group patterns, not personal outcomes.

However, limited information is available for long-term outcomes regarding the maintenance role of the oral formulation. Also, while studies exist comparing Deteron to placebo, comparative evidence is lacking for certain head-to-head comparisons with some other available treatments.


What Remains Uncertain in the Research Landscape

Clinical research, while extensive, always leaves areas where further investigation is needed. Long-term effects are not fully established concerning the complete picture of functional and cognitive outcomes across all populations. Follow-up durations were limited in many of the initial trials, meaning that findings concerning changes measured during the study period may not predict very long-term outcomes. Furthermore, comparative evidence is lacking for certain head-to-head comparisons with some other available treatments, and subgroup findings are uncertain for some specific patient characteristics. This evidence highlights what is known—and what is still uncertain—about Deteron.

Key Studies & References National Institutes of Health (NIH) MedlinePlus Drug Information: Risperidone

Frequently Asked Questions (FAQ)

Common questions about Deteron (FAQ)


Q: Can Deteron be taken at the same time as vitamin supplements?

A: Official guidance recommends informing a healthcare professional about all medicines, vitamins, and supplements being taken. This is to help identify any potential drug interactions or changes in how Deteron works, which helps ensure appropriate use.


Q: Are there any food items that interact with Deteron?

A: According to the official product information, oral tablets and solution can generally be taken with or without food, as food does not clinically affect absorption. However, the official instructions state that the oral solution should not be mixed with tea or cola; it can be mixed with water, coffee, orange juice, or low-fat milk.


Q: How long after starting Deteron do people usually notice an effect?

A: Clinical trial summaries indicate that some psychotic and manic symptoms may begin to show improvement within about one week. However, the full effect of the medicine on behavior, cognition, and mood stabilization may require treatment for several weeks.


Q: Is Deteron considered safe for people with pre-existing kidney issues?

A: Regulatory documents state that use is not recommended for patients who have severe renal impairment, which is defined by official parameters for renal impairment. Patients with moderate kidney impairment require caution and a possible dose adjustment, as detailed in the official prescribing information.


Q: Can Deteron interact with alcohol consumption?

A: Official regulatory documents describe alcohol consumption during treatment as generally not recommended. This is because combining Deteron with alcohol can increase central nervous system (CNS) effects, such as drowsiness, dizziness, and difficulty concentrating.


Q: What if I accidentally miss taking a planned dose of Deteron?

A: Regulatory documentation provides detailed instructions for a missed long-acting injection (LAI) dose. Official guidance describes that a missed LAI dose should be administered as soon as possible, according to the treatment schedule. Since instructions for the oral dose vary widely, consulting a healthcare professional is recommended.


Q: Can Deteron be taken while also using over-the-counter flu medication?

A: Co-administration with other medicines that cause sleepiness or dizziness (such as certain ingredients in over-the-counter flu remedies) may lead to increased sedating effects. For this reason, official guidance supports the assessment of all combined medications by a healthcare professional.


Q: What evidence exists to support the long-term use of Deteron?

A: Studies and official information indicate that the medicine is approved to delay relapse in the long-term treatment of schizophrenia and is often used for maintenance in bipolar disorder. However, long-term functional and cognitive outcomes across all populations are not fully established.


Q: What happens if Deteron is taken with grapefruit juice?

A: Deteron is broken down (metabolized) by certain liver enzymes. Grapefruit juice is known to interfere with some of these enzymes, which may potentially increase the drug's concentration in the bloodstream. It is important for patients to share information about all foods and beverages consumed with their healthcare provider.


Q: What does the official source say about the eligibility of people over 65 for Deteron?

A: Regulatory documents contain a Boxed Warning regarding older adults with dementia-related psychosis, noting an increased risk of death and Cerebrovascular Adverse Events (CVAE). These patients should generally not use the medicine. Other older adults may require a lower starting dose based on regulatory recommendations.


Q: How long does Deteron stay in a person's system after they stop taking it?

A: The elimination half-life of the active substance is approximately 24 hours for the oral forms, meaning the oral drug is quickly processed. The long-acting injection form has a much longer elimination phase, lasting approximately seven to eight weeks after the last injection.


Q: Do official documents mention anything about driving or operating machinery while using Deteron?

A: Official labeling warns that drowsiness and dizziness are common side effects of Deteron. For this reason, regulatory documents advise patients not to drive or operate hazardous machinery until they know how the medicine affects them.


Q: Does Deteron need to be stored in the refrigerator?

A: The long-acting injection kit requires refrigeration (2 C to 8 C), protected from light. Oral tablets and solution can be stored at controlled room temperature (below 25 C or 30 C), but the solution must not be frozen.


Q: Is it normal to feel a mild stomach upset when first using Deteron?

A: Nausea and general gastrointestinal disturbances are noted as common side effects of Deteron in clinical trials. These effects are often more likely to be experienced at the start of treatment or during dose increases.


Q: Is Deteron used to treat common cold symptoms?

A: Deteron is classified as an atypical antipsychotic indicated for conditions like schizophrenia, bipolar disorder, and the short-term management of severe aggression or psychotic symptoms. It is not indicated for the treatment of common cold symptoms.


Q: How quickly does the body process Deteron?

A: The active substance typically reaches steady-state plasma concentrations—a consistent level in the blood—within about four to five days of daily oral dosing. This indicates how quickly the body achieves consistent drug levels.


Q: Does Deteron have different effects on younger versus older adults?

A: The safety and efficacy have not been established for children under 18, and its use is not recommended. Older adults with dementia have an increased risk of serious adverse events. Pediatric patients also commonly show a higher incidence of weight gain.


Q: Is there a generic version of Deteron available?

A: Yes, regulatory agencies like the FDA have approved generic versions of the medicine containing Risperidone. This includes both oral tablets and long-acting injectable formulations, which are considered therapeutically equivalent to the brand-name product.


Q: Can taking Deteron affect the results of common blood tests?

A: Regulatory recommendations include monitoring certain laboratory parameters due to documented potential effects on metabolism and blood cell counts. These tests include Fasting Blood Glucose, a Lipid Panel, and a Complete Blood Count (CBC).


Q: Are there any known interactions between Deteron and common herbal remedies?

A: Regulatory documents describe the combination of Deteron with certain herbal remedies, such as St John’s wort or ginkgo biloba, as generally not recommended. This is because they may interfere with how the medicine works or increase the likelihood of side effects.


Q: How is Deteron thought to affect the body, simply explained?

A: Deteron’s action is described as balancing key natural signaling substances in the brain. It primarily works by regulating the influence of dopamine and serotonin receptors, which helps to stabilize mood and thinking processes.


Q: What information is available regarding the risk of allergic reactions to Deteron?

A: A known hypersensitivity (allergy) to the drug substance or its ingredients is listed in regulatory documents as a contraindication. This classification indicates that the medicine is not appropriate for use by individuals with a documented allergy to it.


Q: Is it mandatory to finish the entire course of Deteron if prescribed?

A: Regulatory information describes that sudden discontinuation or changes in dose are not recommended without professional guidance. This is due to the potential risk of rebound symptoms or the worsening of the underlying condition.


Q: Can Deteron be split or crushed, according to the official instructions?

A: Official instructions specify that orally disintegrating tablets (ODT) are not to be chewed, split, or crushed. Instructions for splitting or crushing standard tablets vary by formulation and should be confirmed with the official label.


Q: Does Deteron have a black box warning in the United States?

A: Yes, the drug carries an FDA Boxed Warning in the United States. This warning concerns the increased risk of death in elderly patients with dementia-related psychosis.


Q: Can Deteron cause changes in mood or behavior?

A: Official literature describes the potential for elevated mood symptoms, such as a manic or hypomanic switch, to occur in susceptible individuals. This risk is noted mainly for those being treated for bipolar disorder or schizophrenia.


Q: What is the relationship between Deteron and liver function?

A: Use of Deteron is not recommended in cases of Severe Hepatic Impairment (poor liver function). Regulatory recommendations include monitoring liver function tests (LFTs) prior to and during treatment due to reported cases of liver enzyme abnormalities.


Q: Does Deteron interact with caffeine?

A: Official instructions for the oral solution indicate it may be mixed with coffee, a source of caffeine. There is no specific regulatory warning against moderate caffeine consumption, suggesting a low interaction risk in typical amounts.


Q: Is there a higher chance of side effects when taking Deteron with other medications?

A: Co-administration with other medicines can lead to additive pharmacodynamic effects. These effects, such as increased CNS depression or hypotension, contribute to a higher likelihood of experiencing certain side effects when multiple medications are used.

How should Deteron be stored and disposed of?

Storage and Disposal Requirements

Official labeling defines specific storage conditions, which vary by the formulation of Deteron (Risperidone) to ensure chemical stability.

Formulation Required Storage Condition
Oral Tablets Controlled room temperature (20 C to 25 C), protected from light and moisture.
Oral Solution Store below 30 C (86 F); do not freeze; protect from light.
Long-Acting Injection Unopened kits require refrigeration (2 C to 8 C), protected from light.

All forms must be kept in the original container and stored out of the sight and reach of children.

For disposal, unused or expired Deteron must not be flushed down the toilet or thrown into household waste. It must be returned to a pharmacy or a designated medicine take-back program. Used injection materials require disposal according to sharps waste procedures.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Deteron found in:

A-Z Index: